Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
Bioorganic & medicinal chemistry letters 2006 Mar 1; 16(5):1397-401
Swahn B BM, Xue Y Y, Arzel E E, Kallin E E, Magnus A A, Plobeck N N, Viklund J J
Department of Medicinal Chemistry, AstraZeneca R&D Södertälje, S-151 85, Södertälje, Sweden. britt-marie.swahn@astrazeneca.com
The design and synthesis of a new series of c-Jun N-terminal kinase-3 (JNK3) inhibitors with selectivity against JNK1 are reported. The novel series of substituted 2'-anilino-4,4'-bipyridines were designed based on a combination of hits from high throughput screening and X-ray crystal structure information of compounds crystallized into the JNK3 ATP binding active site.

